Basel, Switzerland – 20 Sept 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today it is a proud sponsor of the 5th Vasculitis Training Course organized by the European Vasculitis Society (EUVAS) being held 28-30 September in St Gallen, Switzerland. “We are pleased to have Alentis as one of the sponsors for the EUVAS Vasculitis Training Course”, said Dr. David Jayne, co-founder and the current President of EUVAS. “With the training course we aim to provide medical education on vasculitis to physicians, researchers and others interested in vasculitis.”…

Basel, Switzerland – 6 September 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today two company presentations at investor conferences in September and October. UBS Biotechnology Private Company Virtual Symposium The virtual conference is to be held September 20-21, 2023. Roberto Iacone, Chief Executive Officer of Alentis will participate in a fireside chat on Thursday, September 21 at 8:30 am ET. Oppenheimer Private Healthcare Company Showcase The conference is to be held October 11, 2023 at The Intercontinental New York Barclay Hotel. Roberto Iacone will give a company…

Late-Breaking Oral Presentation on ALE.F02 as Potential Treatment for Pulmonary Fibrosis Basel, Switzerland – 29 August 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today an oral presentation during the ERS International Congress to be held September 9-13 in Milan, Italy.Presentation detailsTitle: Claudin-1 is a potential airway-centric therapeutic​ target for pulmonary fibrosis​ (Abstract OA2623)Presenter: Geoffrey Teixeira, SVP Head of Fibrosis, Alentis TherapeuticsSession: #271 - Innovations in pulmonologyDate and time: Monday, 11th September 2023, 11:00 CET“ALE.F02 is being developed to stop progression or reverse organ fibrosis by specifically targeting…

Fast Track designation accelerates the path to US submission for the investigational monoclonal antibody in patients with recurrent or metastatic CLDN1-positive HNSCC Basel, Switzerland – 24 August 2023,  Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC.Fast Track designation aims to facilitate the development and expedite the review of new medicines that intend to treat serious or life-threatening conditions with unmet medical…

The Study Evaluates the Pharmacokinetics of ALE.F02 in Advanced Liver Fibrosis Patients Basel, Switzerland – 13 July 2023,  Alentis  Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the first patient with liver fibrosis has been dosed in the Phase 1b “FEGATO-01” clinical trial of ALE.F02, a CLDN1 targeting investigational antibody for the treatment of liver, kidney, and lung fibrosis. “ALE.F02 can potentially reverse advanced liver fibrosis,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis. “We have a truly differentiated approach of inhibiting pathologically overexpressed CLDN1 to transform…

Santarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Basel, Switzerland – 29 June 2023,  Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis’ board. “I’m pleased to welcome Luca as Chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company,” said Dr. Roberto…

Basel, Switzerland – 21 June 2023, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board. “We are delighted to welcome David and Josep to our newly formed Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis. “They bring tremendous experience and expertise in nephrology and oncology that will be crucial as we advance…

Ph1/2 Clinical Trial in Head and Neck Squamous Cell Carcinoma Expected to Start H2 2023 Basel, Switzerland – 14 June 2023,  Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the FDA cleared an IND application for ALE.C04 as a monotherapy and in combination with pembrolizumab, in a first-in-human clinical trial in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) that is expected to start during the second half of 2023. “With ALE.C04 we aim to treat solid tumors in a unique way. By targeting exposed CLDN1…

Basel, Switzerland – 31 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced its participation in the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 2-6 in Chicago, IL, and the BIO International Convention to be held June 5-8 in Boston, MA. Alentis management will be present at the conferences. In case you want to schedule a meeting please reach out via info@alentis.ch. About Alentis Therapeutics Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is…

The grant supports the development of ALE.C04 for Claudin-1 positive tumors Basel, Switzerland – 9 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced it has been selected to receive a CHF 2.4M grant from the Swiss Accelerator project to further the development of ALE.C04 for Claudin-1 (CLDN1) positive cancers.Of the original 752 applications, the Innosuisse Innovation Council selected 53 projects to receive funding across multiple industries with significant innovation potential. The total funding granted amounts to CHF 112M.“We thank the Innosuisse Innovation Council for recognising Alentis’ work in oncology, and congratulate our fellow winners,” said Dr. Roberto…